Women’s Hormone Therapy After 40: What to Know

Women’s hormonal health after 40 rarely gets a straightforward conversation. The topic is surrounded by decades of conflicting headlines, outdated study references that still shape clinical decisions, and a persistent tendency to normalize symptoms that are clinically significant and often treatable. Most women entering perimenopause — the transitional phase that can begin as early as the late 30s — spend months or years managing a growing list of symptoms before anyone suggests that hormones might be involved.

This article covers what actually happens hormonally after 40, what the symptoms of declining hormone levels look like, what hormone therapy options exist, and what the current evidence says about safety — including the corrections to the 2002 Women’s Health Initiative narrative that reshaped a generation of clinical prescribing.

What Happens Hormonally After 40

The hormonal transition in women after 40 is not a single event — it’s a multi-year process driven by declining ovarian function that affects three primary hormones simultaneously.

Estrogen

Estrogen production — primarily estradiol from the ovaries — begins declining in perimenopause, often erratically rather than steadily. Levels may fluctuate significantly month to month before the sustained decline that characterizes menopause. Estrogen receptors are distributed throughout the body — in the brain, bone, cardiovascular system, urogenital tract, and skin — which explains why estrogen decline produces such a wide-ranging symptom picture.

Progesterone

Progesterone is produced after ovulation from the corpus luteum. As ovulation becomes irregular in perimenopause, progesterone levels become inconsistent before declining substantially. Low progesterone relative to estrogen — sometimes called “estrogen dominance” — is associated with mood changes, sleep disruption, irregular cycles, and anxiety in perimenopausal women. Progesterone also has direct neurosteroid activity in the brain, which makes its decline particularly significant for mood and sleep.

Testosterone

Women produce testosterone — in the ovaries and adrenal glands — at roughly one-tenth the level of men, but it is physiologically important. Testosterone declines gradually from the mid-30s onward and affects libido, energy, muscle mass, and mood. Unlike estrogen and progesterone, testosterone doesn’t drop sharply at menopause — it declines more gradually — but its loss is clinically meaningful and frequently unaddressed.

The interaction between these three hormones, and the timing of their individual declines, explains why perimenopause presents so differently across women and why no single symptom tells the full story.

Symptoms: What Declining Hormones Actually Feel Like

The classic association — hot flashes and missed periods — captures only a fraction of what perimenopause involves. The full symptom picture is broader and frequently attributed to other causes.

Many of these symptoms — particularly mood changes, cognitive fog, sleep disruption, and fatigue — are frequently attributed to stress, depression, or general aging before anyone considers a hormonal cause. This diagnostic delay is one of the primary drivers of unnecessary suffering in perimenopause.

Perimenopause vs. Menopause: The Clinical Distinction

These two terms are often used interchangeably, but they describe different clinical stages with different management implications.

Perimenopause is the transitional phase leading up to menopause, typically lasting 4–8 years (sometimes longer). It is characterized by hormonal fluctuation — estrogen and progesterone may swing widely — rather than consistent decline. Cycles become irregular. Symptoms may be episodic and variable. Perimenopause begins on average in the mid-40s, but can start in the late 30s.

Menopause is defined retrospectively as 12 consecutive months without a menstrual period. The average age of natural menopause in the U.S. is 51–52. At this point, ovarian hormone production has declined substantially and symptoms typically stabilize in pattern, though they may intensify.

Postmenopause is the period following menopause. Without hormone therapy, estrogen, progesterone, and testosterone remain at low levels indefinitely — and the long-term consequences for bone density, cardiovascular health, and cognitive function accumulate over time.

Diagnosing perimenopause requires clinical history combined with laboratory assessment. A single FSH measurement is insufficient — levels fluctuate significantly during perimenopause. A comprehensive panel including estradiol, FSH, progesterone, testosterone, and thyroid markers provides a more complete picture and guides treatment decisions.

Hormone Therapy Options: What’s Available

Hormone therapy (HT) for women after 40 encompasses several different approaches — and the terminology has evolved significantly. “HRT” (hormone replacement therapy) has largely been replaced by “MHT” (menopausal hormone therapy) or simply “HT” in current clinical guidelines, reflecting the shift from framing it as replacing something lost to treating a clinical condition.

Estrogen therapy

Estrogen alone — without progestogen — is appropriate only for women who have had a hysterectomy, as estrogen alone in women with an intact uterus increases endometrial cancer risk. Estrogen is available in multiple forms: oral tablets, transdermal patches, topical gels and creams, vaginal rings, and vaginal tablets or cream (for localized GSM treatment). Transdermal estrogen is generally preferred over oral for women with cardiovascular risk factors, as it avoids first-pass liver metabolism.

Combined estrogen-progestogen therapy

Women with an intact uterus require progestogen alongside estrogen to protect the endometrium. Progestogen options include synthetic progestins (medroxyprogesterone acetate, norethisterone) and bioidentical progesterone (micronized progesterone, brand name Prometrium). Research suggests that micronized progesterone may have a more favorable safety profile than synthetic progestins — particularly regarding breast cancer risk and cardiovascular markers — though evidence continues to evolve.

Testosterone therapy in women

Testosterone therapy for women remains significantly underutilized despite solid evidence for its effectiveness in treating sexual dysfunction — specifically hypoactive sexual desire disorder (HSDD) and related symptoms. The 2019 Global Consensus Position Statement on testosterone therapy in women, endorsed by major endocrine and sexual medicine societies, concluded that testosterone therapy at physiological doses is safe and effective for women with HSDD. No testosterone product is FDA-approved specifically for women in the U.S. — meaning all use is off-label, but it is supported by clinical guidelines and extensive research.

Local vaginal hormone therapy

For women whose primary concern is genitourinary symptoms — vaginal dryness, discomfort, recurrent UTIs, urinary urgency — low-dose vaginal estrogen (cream, ring, or tablet) or prasterone (DHEA) suppositories address these symptoms with minimal systemic absorption. These are appropriate for women who want to address GSM without systemic HT, and are generally considered safe even in women with a history of certain hormone-sensitive cancers when used at approved local doses.

Table 1 — Hormone therapy options for women after 40. This is a general overview; treatment selection requires physician evaluation including medical history, symptom profile, and risk assessment.

The WHI Study: Setting the Record Straight

No discussion of women’s hormone therapy is complete without addressing the Women’s Health Initiative (WHI) — the 2002 study that caused widespread abandonment of HRT and reshaped clinical prescribing for decades.

The WHI enrolled postmenopausal women aged 50–79 (average age 63) and evaluated a specific combination of oral conjugated equine estrogen and medroxyprogesterone acetate (a synthetic progestin). The study was stopped early based on findings of increased breast cancer, coronary heart disease, stroke, and blood clots in the hormone group compared to placebo.

What followed was appropriate for those specific findings in that specific population — but the interpretation was broadly generalized to all hormone therapy, in all women, at all ages. Subsequent re-analysis and decades of additional research have significantly revised this picture:

• The elevated cardiovascular risk was concentrated in women who were more than 10 years past menopause when they started therapy — not in women who started HT near menopause onset (“the timing hypothesis” or “window of opportunity”)
• Women aged 50–59 who started estrogen alone actually showed a trend toward reduced cardiovascular mortality in the WHI data
• The synthetic progestin (medroxyprogesterone acetate) used in WHI is not equivalent to micronized bioidentical progesterone — studies using the latter show a more favorable risk profile
• Transdermal estrogen avoids the clotting and stroke risks associated with oral estrogen, which undergoes first-pass liver metabolism

Current guidelines from the North American Menopause Society (NAMS), the British Menopause Society, and the Endocrine Society reflect this updated evidence. For most healthy women under 60 or within 10 years of menopause onset, the benefits of HT for symptom relief and long-term health preservation outweigh the risks when appropriately selected and monitored.

The Testosterone Question in Women: Underrecognized and Undertreated

Testosterone’s role in women’s health remains one of the most underrecognized areas of clinical practice. The 2019 Global Consensus Position Statement — developed by an international panel representing the major endocrine, menopause, and sexual medicine societies — concluded that:

• Testosterone therapy at physiological levels is effective for hypoactive sexual desire disorder in postmenopausal women
• Evidence supports improvements in sexual function, including desire, arousal, and satisfaction
• Physiological testosterone doses do not increase cardiovascular risk or breast cancer risk based on current evidence
• No testosterone product is FDA-approved for women in the U.S. — an off-label prescribing situation that reflects a regulatory gap, not an evidence gap

Women experiencing reduced libido, fatigue, reduced muscle mass, and mood changes alongside other hormonal symptoms should have testosterone levels assessed alongside estrogen and progesterone as part of a comprehensive hormonal evaluation. The relationship between testosterone and sexual health in women parallels aspects of what is seen in men — though at very different physiological levels. The overview of sexual health services covers how hormonal factors contribute to sexual function across both sexes.

How Does Women’s HRT Compare to TRT in Men?

The parallel between men’s and women’s hormonal therapy is clinically instructive — and patients who understand both benefit from the comparison.

Table 2 — Comparison of women’s and men’s hormonal therapy. Both require physician-confirmed deficiency, appropriate delivery method selection, and ongoing monitoring. For the full TRT overview, see the complete guide to testosterone replacement therapy.

What a Proper Evaluation Looks Like

A thorough hormonal evaluation for women after 40 goes beyond a single hormone panel. A complete initial workup typically includes:

Frequently Asked Questions

Is hormone therapy safe for women after 40?

For most healthy women under 60 or within 10 years of menopause onset, current evidence supports that the benefits of hormone therapy outweigh the risks when appropriately selected and monitored. The key variables are: type of hormone used (bioidentical vs. synthetic), route of delivery (transdermal vs. oral), timing of initiation (near vs. remote from menopause), individual cardiovascular and cancer risk factors, and duration of use. A physician assessment that accounts for all these variables is the appropriate framework — not a blanket yes or no based on 2002 WHI headlines.

What is “bioidentical” hormone therapy?

Bioidentical hormones have a molecular structure identical to the hormones produced by the human body — estradiol, progesterone, testosterone. They can be FDA-approved (micronized progesterone, estradiol patches, gels) or compounded by a pharmacy per physician prescription. The term is sometimes used loosely in marketing contexts to include custom-compounded preparations that may not have the same quality controls as FDA-approved products. When a physician prescribes bioidentical hormones through a licensed compounding pharmacy based on individual hormone testing, this is a legitimate clinical approach — but the quality of compounding varies significantly between pharmacies.

When should I consider hormone therapy?

Hormone therapy should be considered when symptoms of hormonal decline are affecting quality of life, and when laboratory evaluation confirms the hormonal picture consistent with those symptoms. There is no single threshold — the decision is individualized. Most guidelines support initiating HT in the perimenopausal or early postmenopausal period for maximum benefit, particularly for long-term cardiovascular and bone health protection alongside symptom relief. Starting HT more than 10 years after menopause is approached more cautiously.

Does hormone therapy cause breast cancer?

The relationship between HT and breast cancer is complex and depends on the specific regimen used. Estrogen alone (in women without a uterus) does not appear to increase breast cancer risk and may slightly reduce it based on WHI and subsequent data. Estrogen combined with synthetic progestins showed a small increased risk in WHI — roughly equivalent to the risk associated with having one alcoholic drink per day. Estrogen combined with micronized progesterone shows a more favorable risk profile in several European studies. Individual risk assessment based on personal and family history is essential. For the majority of women without significant baseline risk factors, the absolute risk is small, and for many, symptom relief and long-term health benefits outweigh it.

Can I start hormone therapy if I still have periods?

Yes — perimenopausal HT is appropriate for women who are still cycling but experiencing significant symptoms. The approach differs from postmenopausal HT because hormone levels are still fluctuating. Sequential progesterone regimens (progesterone taken cyclically rather than continuously) are typically used in perimenopausal women with an intact uterus to accommodate ongoing cycles. Dosing and timing are different from postmenopausal protocols and require physician management.

How is testosterone therapy different for women than for men?

The physiological range for testosterone in women is roughly one-tenth of male levels — typically 15–70 ng/dL versus 300–1000 ng/dL in men. Treatment goals for women aim to restore levels to the upper-normal premenopausal range, not to male-level ranges. Delivery is typically through low-dose compounded testosterone cream or gel applied to the skin. The effects are clinically significant at these low doses — libido, energy, mood, muscle — but very different in magnitude and character from male androgen effects. Dosing errors (too high) can produce androgenic side effects like acne, hair changes, and clitoral sensitivity, which is why physician monitoring is required. For more on how testosterone affects sexual function, the overview of libido and hormonal causes covers the parallels and differences.

Does hormone therapy help with weight management after menopause?

Hormone therapy can support body composition in menopausal women — specifically by reducing the shift toward visceral fat accumulation that accelerates after menopause when estrogen declines. Studies show that HT attenuates menopausal changes in fat distribution and helps preserve lean mass. It is not a weight loss treatment — total body weight effects are modest — but body composition effects (less visceral fat, more preserved muscle) are consistent with the hormonal mechanism. Weight management concerns after menopause, including GLP-1 therapy options, are covered in the weight loss overview.

How long can hormone therapy be continued?

There is no universal maximum duration for HT. Older guidelines suggested limiting use to 3–5 years, but current guidelines from NAMS, the British Menopause Society, and the Endocrine Society have moved away from arbitrary time limits in favor of individualized benefit-risk assessment. Women who continue to have symptoms and whose risk profile is favorable may continue HT indefinitely under physician supervision with periodic reassessment. The question of duration is best addressed annually with a physician who is tracking both symptoms and health markers.

References

1. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321–333. doi:10.1001/jama.288.3.321
2. Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA. 2013;310(13):1353–1368. doi:10.1001/jama.2013.278040
3. Davis SR, Baber R, Panay N, et al. Global Consensus Position Statement on the Use of Testosterone Therapy for Women. J Clin Endocrinol Metab. 2019;104(10):4660–4666. doi:10.1210/jc.2019-01603
4. The NAMS 2022 Hormone Therapy Position Statement Advisory Panel. The 2022 hormone therapy position statement of The Menopause Society. Menopause. 2022;29(7):767–794. doi:10.1097/GME.0000000000002028
5. Stuenkel CA, Davis SR, Gompel A, et al. Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2015;100(11):3975–4011. doi:10.1210/jc.2019-01603″ target=”_blank” rel=”noopener noreferrer”>doi:10.1210/jc.2015-2236
6. Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk. Lancet. 2019;394(10204):1159–1168. doi:10.1016/S0140-6736(19)31709-X
7. Hodis HN, Mack WJ. Menopausal Hormone Replacement Therapy and Reduction of All-Cause Mortality and Cardiovascular Disease. Nat Rev Endocrinol. 2022;18(8):499–512. doi:10.1038/s41574-022-00678-z